North Dakota State Investment Board Invests $5.58 Million in Gilead Sciences, Inc. $GILD

North Dakota State Investment Board purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, HoldingsChannel.com reports. The firm purchased 45,461 shares of the biopharmaceutical company’s stock, valued at approximately $5,580,000.

Several other hedge funds and other institutional investors have also modified their holdings of GILD. Ares Financial Consulting LLC purchased a new position in shares of Gilead Sciences during the fourth quarter worth $28,000. Financial Consulate Inc. boosted its position in shares of Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 109 shares during the period. North Star Investment Management Corp. boosted its position in shares of Gilead Sciences by 54.8% during the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 86 shares during the period. MTM Investment Management LLC boosted its position in shares of Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 176 shares during the period. Finally, BOCHK Asset Management Ltd purchased a new position in shares of Gilead Sciences during the fourth quarter worth $31,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total value of $1,291,600.00. Following the sale, the chief executive officer directly owned 632,567 shares in the company, valued at $81,702,353.72. This trade represents a 1.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total value of $422,880.00. Following the completion of the sale, the insider owned 128,779 shares in the company, valued at approximately $18,152,687.84. This represents a 2.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 63,000 shares of company stock worth $9,238,250 over the last ninety days. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $129.58 on Monday. The stock has a market cap of $160.88 billion, a P/E ratio of 17.65 and a beta of 0.31. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 12-month low of $100.23 and a 12-month high of $157.29. The business’s fifty day simple moving average is $137.76 and its 200-day simple moving average is $133.31.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. During the same period last year, the firm earned $1.81 earnings per share. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post -0.78 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be paid a $0.82 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Analysts Set New Price Targets

Several research firms have recently commented on GILD. Morgan Stanley lowered their price target on Gilead Sciences from $175.00 to $168.00 in a research report on Friday, May 8th. Citigroup increased their price objective on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Leerink Partners reduced their price objective on Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. Argus increased their price objective on Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Finally, Weiss Ratings upgraded Gilead Sciences from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, May 11th. Twenty-four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $157.04.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.